Effects of daily consumption of the probiotic Bifidobacterium animalis subsp. lactis CECT 8145 on anthropometric adiposity biomarkers in abdominally obese subjects: A randomized controlled trial 

This 2019 randomized double blind placebo controlled clinical trial was conducted to understand HT BPL1’s role in the management of metabolic health. Participants (n = 135) consumed 1 capsule/day containing 1010 colony forming unit (CFU) of Ba8145 or placebo (maltodextrin) for 3 months. 39% of study subjects in the HT BPL1 intervention group experienced a decrease in waist circumference of ≥ 2cm at 12 weeks. Participants taking BPL1 saw a significant decrease in central adiposity (as measured by the Conicity Index) after 12 weeks, compared to baseline. Participants taking BPL1 showed a statistically significant decrease in body mass index (BMI) compared to placebo at 12 weeks of the intervention period. 

References:

Pedret A, Valls RM, Calderón-Pérez L, et al.. Effects of daily consumption of the probiotic Bifidobacterium animalis subsp. lactis CECT 8145 on anthropometric adiposity biomarkers in abdominally obese subjects: a randomized controlled trial. Int J Obes (Lond). 2019 Sep;43(9):1863-1868. doi: 10.1038/s41366-018-0220-0. Epub 2018 Sep 27. PMID: 30262813; PMCID: PMC6760601.